{'fraction_non_alphanumeric': 0.04067402672864614, 'fraction_numerical': 0.051714119697850086, 'mean_word_length': 4.609120521172638, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Diuretic Lounge and the Impact on Hospital Admissions for Treatment of Decompensated Heart Failure.

BACKGROUND
Heart failure is a prevalent condition associated with frequent and costly hospital admissions. Hospitalisations are primarily related to worsening fluid retention and often require admission for decongestion with intravenous diuretics.


OBJECTIVE
To assess the safety of an outpatient intravenous diuresis service for heart failure patients, and its impact on emergency admissions and the cost of treatment.


METHODS
We conducted a prospective observational cohort registry study on patients referred to the diuretic lounge at our acute hospital between May 2017 and April 2018.


RESULTS
We analysed 245 patients treated in the diuretic lounge, of which 190 (77.6%) avoided hospitalisation or any adverse events during the 60 days of follow up (77.6% vs. 22.4%; P < 0.001). The diuretic lounge service resulted in a significant decrease in emergency heart failure admissions compared to the previous 12 months (823 vs. 715 per annum; 68.6 ± 10.1 vs. 59.6 ± 14 per month; P = 0.04), and a numerical reduction in readmission rates (17.3% vs. 16.2%). The 13.1% decrease in admissions lead to financial savings of £315,497 per annum and £2,921 per admission avoided. During the same time period, at the other acute hospital site in our trust, where no diuretic lounge service is available, the number of admissions did not significantly change (457 vs. 450 per annum; 37.5 ± 7.0 vs. 38.1 ± 7.6 per month; P = 0.81).


CONCLUSION
Ambulatory administration of intravenous diuretics reduces emergency admissions and is a safe and cost effective alternative to treat acute decomposition in heart failure patients.